MedTrace Logo

BHT-3009 Immunotherapy in Relapsing Remitting Multiple Sclerosis

NCT00382629 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 252

Last updated 2008-02-11

No results posted yet for this study

Summary

The purpose of this study is to determine if BHT-3009 decreases inflammation (measured by gadolinium enhancing MRI lesions) in the brains of people with relapsing remitting multiple sclerosis.

Conditions

  • Relapsing Remitting Multiple Sclerosis

Interventions

DRUG

BHT-3009 0.5 mg

DRUG

BHT-3009 1.5 mg

DRUG

Placebo

Sponsors & Collaborators

  • Bayhill Therapeutics

    lead INDUSTRY

Principal Investigators

  • Frank Valone, MD · Bayhill Therapeutics

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
55 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2006-02-28
Completion
2007-06-30

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00382629 on ClinicalTrials.gov